CN102143687B - 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途 - Google Patents

4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途 Download PDF

Info

Publication number
CN102143687B
CN102143687B CN201080002517.4A CN201080002517A CN102143687B CN 102143687 B CN102143687 B CN 102143687B CN 201080002517 A CN201080002517 A CN 201080002517A CN 102143687 B CN102143687 B CN 102143687B
Authority
CN
China
Prior art keywords
aminopyridine
impairment
patient
neurocognitive
neuropsychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080002517.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102143687A (zh
Inventor
托马斯·C·韦赛尔
A·布莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of CN102143687A publication Critical patent/CN102143687A/zh
Application granted granted Critical
Publication of CN102143687B publication Critical patent/CN102143687B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201080002517.4A 2009-08-11 2010-08-11 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途 Expired - Fee Related CN102143687B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23307709P 2009-08-11 2009-08-11
US23306909P 2009-08-11 2009-08-11
US61/233,069 2009-08-11
US61/233,077 2009-08-11
US23987709P 2009-09-04 2009-09-04
US61/239,877 2009-09-04
PCT/US2010/045211 WO2011019845A1 (en) 2009-08-11 2010-08-11 Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Publications (2)

Publication Number Publication Date
CN102143687A CN102143687A (zh) 2011-08-03
CN102143687B true CN102143687B (zh) 2015-11-25

Family

ID=43586462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080002517.4A Expired - Fee Related CN102143687B (zh) 2009-08-11 2010-08-11 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途

Country Status (17)

Country Link
US (8) US20130053420A1 (enExample)
EP (1) EP2464229B1 (enExample)
JP (2) JP6137833B2 (enExample)
KR (2) KR20170128633A (enExample)
CN (1) CN102143687B (enExample)
AR (1) AR077858A1 (enExample)
AU (1) AU2010282509B2 (enExample)
BR (1) BRPI1003991A2 (enExample)
CA (1) CA2770698C (enExample)
ES (1) ES2563751T3 (enExample)
JO (1) JO3348B1 (enExample)
MX (1) MX2012001814A (enExample)
RU (1) RU2563821C2 (enExample)
TW (2) TWI549678B (enExample)
UY (1) UY32837A (enExample)
WO (1) WO2011019845A1 (enExample)
ZA (1) ZA201201001B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
US20130030025A1 (en) * 2011-01-28 2013-01-31 Wessel Thomas C Use of potassium channel blockers to treat cerebral palsy
US10793893B2 (en) 2011-06-30 2020-10-06 Serb Sa Methods of administering 3,4-diaminopyridine
WO2014138298A1 (en) * 2013-03-05 2014-09-12 University Of Chicago Treatment of demyelinating disorders
EP3427735A1 (en) * 2013-04-15 2019-01-16 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
DE102014221687B4 (de) * 2014-10-24 2019-07-04 Danfoss Silicon Power Gmbh Leistungshalbleitermodul mit kurzschluss-ausfallmodus
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072025A2 (en) * 2001-03-14 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Improving postsynaptic response by a combination of 4-minopyridine and agonist
US20050228030A1 (en) * 2004-04-09 2005-10-13 Blight Andrew R Method of using sustained release aminopyridine compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072025A2 (en) * 2001-03-14 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Improving postsynaptic response by a combination of 4-minopyridine and agonist
US20050228030A1 (en) * 2004-04-09 2005-10-13 Blight Andrew R Method of using sustained release aminopyridine compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aminopyridines for symptomatic treatment in multiplesclerosis(Review);Solari A,等;《The Cochrane Collaboration》;20090121(第1期);第3页主要结果 *

Also Published As

Publication number Publication date
KR20120050473A (ko) 2012-05-18
JP6137833B2 (ja) 2017-05-31
RU2012108656A (ru) 2013-09-20
ES2563751T3 (es) 2016-03-16
ZA201201001B (en) 2014-10-29
CN102143687A (zh) 2011-08-03
UY32837A (es) 2011-03-31
AU2010282509B2 (en) 2015-07-30
TWI549678B (zh) 2016-09-21
US20190015399A1 (en) 2019-01-17
KR20170128633A (ko) 2017-11-22
EP2464229B1 (en) 2015-11-25
RU2563821C2 (ru) 2015-09-20
BRPI1003991A2 (pt) 2015-09-15
US20180147193A1 (en) 2018-05-31
TW201613585A (en) 2016-04-16
TW201110967A (en) 2011-04-01
CA2770698A1 (en) 2011-02-17
JO3348B1 (ar) 2019-03-13
EP2464229A1 (en) 2012-06-20
AR077858A1 (es) 2011-09-28
US20170281608A1 (en) 2017-10-05
WO2011019845A1 (en) 2011-02-17
MX2012001814A (es) 2012-06-01
US20200113882A1 (en) 2020-04-16
EP2464229A4 (en) 2013-02-13
JP2016074728A (ja) 2016-05-12
US20190247379A1 (en) 2019-08-15
US20160213661A1 (en) 2016-07-28
US20170056385A1 (en) 2017-03-02
JP2013501805A (ja) 2013-01-17
HK1173911A1 (zh) 2013-05-31
CA2770698C (en) 2018-01-30
AU2010282509A1 (en) 2012-03-01
US20130053420A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
TW201010703A (en) Methods of using sustained release aminopyridine compositions
US20170035742A1 (en) Durable treatment with 4-aminopyridine in patients with demyelination
TW201408300A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及氨吡啶（ｆａｍｐｒｉｄｉｎｅ）之組合治療多發性硬化症
CN119584962A (zh) T型钙通道调节剂的使用方法
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
HK1173911B (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with multiple sclerosis
HK40017808A (en) Methods of treating seizure disorders
OA16802A (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125